Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Kura Oncology (KURA) Gains from Sales and Divestitures (2025)

Kura Oncology has reported Gains from Sales and Divestitures over the past 1 years, most recently at $401000.0 for Q4 2025.

Quarterly Gains from Sales and Divestitures changed N/A to $401000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $401000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $401000.0 for FY2025, N/A changed from the prior year.
Gains from Sales and Divestitures was $401000.0 for Q4 2025 at Kura Oncology.
Over five years, Gains from Sales and Divestitures peaked at $401000.0 in Q4 2025 and troughed at $401000.0 in Q4 2025.